Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Antilysin
2. Basic Pancreatic Trypsin Inhibitor
3. Bovine Kunitz Pancreatic Trypsin Inhibitor
4. Bovine Pancreatic Trypsin Inhibitor
5. Bpti, Basic Pancreatic Trypsin Inhibitor
6. Contrical
7. Contrykal
8. Dilmintal
9. Inactivator, Kallikrein-trypsin
10. Iniprol
11. Kallikrein Trypsin Inactivator
12. Kallikrein-trypsin Inactivator
13. Kontrikal
14. Kontrykal
15. Kunitz Pancreatic Trypsin Inhibitor
16. Pulmin
17. Traskolan
18. Trasylol
19. Trypsin Inhibitor, Basic, Pancreatic
20. Trypsin Inhibitor, Kunitz, Pancreatic
21. Zymofren
1. Iniprol
2. Trazinin
3. Zymofren
4. Trasylol
5. Bpti
6. Riker 52g
7. Bayer A 128
8. Pancreatic Trypsin Inhibitor
9. Rp-9921
10. 9087-70-1
11. Antilysine
12. Aprotinina
13. Aprotinine
14. Aprotininum
15. Antagosan
16. Antikrein
17. Contrykal
18. Inhibin
19. Onquinin
20. Pantinol
21. Protimbin
22. Repulson
23. Trascolan
24. Fosten
25. Gordox
26. Tzalol
27. Kir Richter
28. Trypsin Inhibitor
29. Aprotinin Solution
30. Aprotinin Bovine
31. Basic Protease Inhibitor
32. Aprotinine [inn-french]
33. Aprotininum [inn-latin]
34. Aprotinina [inn-spanish]
35. Unii-04xpw8c0fl
36. 04xpw8c0fl
37. Kallikrein-trypsin Inactivator
38. Kunitz And Northrop Inhibitor
39. Basic Protease Inhibitor (bpi)
40. Baya0128
41. Gtpl6570
42. Hsdb 7502
43. Aprotinin [usan:usp:inn:ban]
44. Basic Pancreatic Trypsin Inhibitor
45. Pancreatic Basic Trypsin Inhibitor
46. Trypsin Inhibitor, Pancreatic Basic
47. Einecs 232-994-9
48. Pancreatic Trypsin Inhibitor (kunitz)
49. Trypsin-kallikrein Inhibitor (kunitz)
50. Rp 9921
51. Rpdfcleppytgpckariiryfynakaglcqtfvyggcrakrnnfksaedcmrtcgga
| Molecular Weight | 6511 g/mol |
|---|---|
| Molecular Formula | C284H432N84O79S7 |
| XLogP3 | -25.4 |
| Hydrogen Bond Donor Count | 93 |
| Hydrogen Bond Acceptor Count | 97 |
| Rotatable Bond Count | 111 |
| Exact Mass | 6510.0514478 g/mol |
| Monoisotopic Mass | 6507.0413833 g/mol |
| Topological Polar Surface Area | 2820 Ų |
| Heavy Atom Count | 454 |
| Formal Charge | 0 |
| Complexity | 16700 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 57 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Aprotinin is indicated to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft (CABG) surgery who are at an increased risk for blood loss and blood transfusion. /Included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007.
Aprotinin has also been studied for use in the reduction of bleeding and transfusion requirements in other types of surgery including orthotopic liver transplantation, total hip replacement, colorectal surgery, peripheral vascular surgery, and heart and heart-lung transplantation . Study results evaluating the use of aprotinin for these indications are preliminary. Further studies are required to assess aprotinin's efficacy in these indications. /Not included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007.
Aprotinin was originally introduced for the treatment of acute pancreatitis because of its proteinase inhibiting property. However, most studies have failed to show any benefit from this use. /Not included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007.
The use of aprotinin to control bleeding in emergency cardiac surgery after thrombolysis with alteplase, streptokinase, or urokinase has been reported. Although aprotinin may be effective in preventing severe hemorrhage in this setting, controlled studies to verify its efficacy and safety have not been done. /Not included US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007.
Use of aprotinin for the treatment of subcutaneous insulin resistance syndrome has been described in a limited number of case reports from the early 1980s. /Not included in US product label/
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007.
/SIGNS AND SYMPTOMS/ ... Bayer HealthCare Pharmaceuticals Inc. has notified the FDA that the company will begin removing the remaining Trasylol stock from the U.S. market, most of which is in warehouses and hospital or physician's stock. The FDA will work with Bayer to ensure a smooth and complete process. Under a limited use agreement, access to Trasylol is limited to investigational use of the drug according to the procedures described in a special treatment protocol. The protocol allows treatment for certain patients who are at increased risk of blood loss and transfusions during coronary artery bypass graft surgery and who have no acceptable alternative therapy. Physicians using Trasylol in this situation must also verify that the benefits of the drug clearly outweigh the risks for their patients. ... Results from a randomized Canadian study ... suggest that Trasylol appears to increase the risk for death compared to two other antifibrinolytic drugs used in the study.... The FDA has not yet received full study data from the study's researchers at the Ottawa Health Research Institute but supports Bayer's decision to completely remove Trasylol from regular use in the U.S. market. FDA is also reviewing the available Canadian study data to reassess the currently active special treatment protocol that provides access to Trasylol. ...
FDA; FDA News - Manufacturer Removes Remaining Stocks of Trasylol: Access Limited to Investigational Use (May 2008). Available from, as of May 19, 2008: https://www.fda.gov/bbs/topics/NEWS/2008/NEW01834.html
/SIGNS AND SYMPTOMS/ The U.S. Food and Drug Administration (FDA) today /November 5, 2007/ announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death. FDA requested the suspension in the interest of patient safety based on the serious nature of the outcomes suggested in the preliminary data. FDA has not yet received full study data but expects to act quickly with Bayer, the study's researchers at the Ottawa Health Research Institute, and other regulatory agencies to undertake a thorough analysis of data to better understand the risks and benefits of Trasylol. There are not many treatment options for patients at risk for excessive bleeding during cardiac surgery. Thus, FDA is working with Bayer to phase Trasylol out of the marketplace in a way that does not cause shortages of other drugs used for this purpose. Until FDA can review the data from the terminated study it is not possible to determine and identify a population of patients undergoing cardiac surgery for which the benefits of Trasylol outweigh the risks. Understanding that individual doctors may identify specific cases where benefit outweighs risk, FDA is committed to exploring ways for those doctors to have continued, limited access to Trasylol. ...
FDA; FDA News - FDA Requests Marketing Suspension of Trasylol (November 2007). Available from, as of May 19, 2008: https://www.fda.gov/bbs/topics/NEWS/2007/NEW01738.html
/SIGNS AND SYMPTOMS/ In this multicenter, blinded trial, /the investigators/ randomly assigned 2331 high-risk cardiac surgical patients to one of three groups: 781 received aprotinin, 770 received tranexamic acid, and 780 received aminocaproic acid. The primary outcome was massive postoperative bleeding. Secondary outcomes included death from any cause at 30 days. The trial was terminated early because of a higher rate of death in patients receiving aprotinin. A total of 74 patients (9.5%) in the aprotinin group had massive bleeding, as compared with 93 (12.1%) in the tranexamic acid group and 94 (12.1%) in the aminocaproic acid group (relative risk in the aprotinin group for both comparisons, 0.79; 95% confidence interval [CI], 0.59 to 1.05). At 30 days, the rate of death from any cause was 6.0% in the aprotinin group, as compared with 3.9% in the tranexamic acid group (relative risk, 1.55; 95% CI, 0.99 to 2.42) and 4.0% in the aminocaproic acid group (relative risk, 1.52; 95% CI, 0.98 to 2.36). The relative risk of death in the aprotinin group, as compared with that in both groups receiving lysine analogues, was 1.53 (95% CI, 1.06 to 2.22). Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin, as compared with the lysine analogues, precludes its use in high-risk cardiac surgery.
PMID:18480196 Fergusson DA et al; N Engl J Med.; 358 (22): 2319-31 (2008)
The U.S. Food and Drug Administration (FDA) has approved revised labeling for Trasylol (aprotinin injection) to strengthen its safety warnings and to limit its approved usage to specific situations. Trasylol is given to patients before heart surgery to reduce bleeding and the need for blood transfusions. ... FDA announced on September 29, 2006, that Bayer informed the agency of a safety study on September 27, 2006. The preliminary results from that study suggest that in addition to serious kidney damage, Trasylol may increase the chance for death, congestive heart failure (a weakening of the heart), and strokes. The FDA review of this additional Trasylol safety information is continuing and it may result in other actions, including additional changes to the labeling.
US FDA; FDA News (12/15/2006). Available from, as of March 28, 2007: https://www.fda.gov/bbs/topics/NEWS/2006/NEW01529.html
For more Drug Warnings (Complete) data for APROTININ (29 total), please visit the HSDB record page.
For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
FDA Label
Aprotinin is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. Aprotinin, through its inhibition of multiple mediators [e.g., kallikrein, plasmin] results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation. Aprotinin inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b). The effects of aprotinin use in CPB involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.
Hemostatics
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure. (See all compounds classified as Hemostatics.)
Serine Proteinase Inhibitors
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES. (See all compounds classified as Serine Proteinase Inhibitors.)
Trypsin Inhibitors
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds. (See all compounds classified as Trypsin Inhibitors.)
B - Blood and blood forming organs
B02 - Antihemorrhagics
B02A - Antifibrinolytics
B02AB - Proteinase inhibitors
B02AB01 - Aprotinin
Absorption
100% (IV)
Route of Elimination
Following a single IV dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours. After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug. After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.
After intravenous (iv) injection, rapid distribution of aprotinin occurs into the total extracellular space, leading to a rapid initial decrease in plasma aprotinin concentration.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
Following a single iv dose of radiolabelled aprotinin, approximately 25-40% of the radioactivity is excreted in the urine over 48 hours. After a 30 minute infusion of 1 million KIU, about 2% is excreted as unchanged drug. After a larger dose of 2 million KIU infused over 30 minutes, urinary excretion of unchanged aprotinin accounts for approximately 9% of the dose.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
Animal studies have shown that aprotinin is accumulated primarily in the kidney. Aprotinin, after being filtered by the glomeruli, is actively reabsorbed by the proximal tubules in which it is stored in phagolysosomes.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
There are no available studies on the distribution of aprotinin into breast milk.
Thomson/Micromedex. Drug Information for the Health Care Professional. Volume 1, Greenwood Village, CO. 2007.
For more Absorption, Distribution and Excretion (Complete) data for APROTININ (9 total), please visit the HSDB record page.
Aprotinin is slowly degraded by lysosomal enzymes.
Aprotinin is slowly degraded by lysosomal enzymes. The physiological renal handling of aprotinin is similar to that of other small proteins, e.g., insulin.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
Following this distribution phase, a plasma half-life of about 150 minutes is observed. At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.
Following this distribution phase, a plasma half-life of about 150 minutes is observed. At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
Aprotinin inhibits serine proteases including trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/mL, and kallikrein at 300,000 IU/mL. The inhibition of kallikrein inhibits formation of factor XIIa. This inhibits the intrinsic pathway of coagulation and fibrinolysis. Inhibition of plasmin also slows fibrinolysis.
Aprotinin is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. Aprotinin, through its inhibition of multiple mediators (e.g., kallikrein, plasmin) results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
Aprotinin inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b).
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
The effects of aprotinin use in ... /cardiopulmonary bypass/ involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.
Physicians Desk Reference 61st ed, Thomson PDR, Montvale, NJ 2007., p. 754
Aprotinin is thought to improve hemostasis during and after cardiopulmonary bypass by preserving platelet membrane receptors that maintain the adhesive and aggregative capacity of platelets. In addition, aprotinin inhibits fibrinolysis through inhibition of plasmin and plasma and tissue kallikreins. Because of its effects on kallikrein, aprotinin also inhibits activation of the intrinsic clotting system (i.e., contact phase of coagulation), a process that both initiates coagulation and promotes fibrinolysis. The relative contribution of these effects of aprotinin to the drug's therapeutic action remains to be fully elucidated.
McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2007., p. 1574
For more Mechanism of Action (Complete) data for APROTININ (6 total), please visit the HSDB record page.
API SUPPLIERS
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : R0-CEP 2000-385 - Rev 01
Issue Date : 2005-02-18
Type : TSE
Substance Number : 579
Status : Expired
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28780
Submission : 2014-08-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26253
Submission : 2012-07-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4273
Submission : 1981-07-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2000-161 - Rev 03
Issue Date : 2011-09-15
Type : Chemical and TSE
Substance Number : 579
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9829
Submission : 1992-08-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6296
Submission : 1986-04-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6299
Submission : 1986-04-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16315
Submission : 2002-12-17
Status : Inactive
Type : II
Certificate Number : R1-CEP 2000-214 - Rev 04
Issue Date : 2009-02-06
Type : TSE
Substance Number : 694
Status : Valid
Certificate Number : R1-CEP 2000-218 - Rev 03
Issue Date : 2009-02-06
Type : TSE
Substance Number : 694
Status : Valid
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9829
Submission : 1992-08-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4273
Submission : 1981-07-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26253
Submission : 2012-07-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28780
Submission : 2014-08-15
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16315
Submission : 2002-12-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6296
Submission : 1986-04-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6299
Submission : 1986-04-18
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Aprotinin concentrated solution
Certificate Number : R0-CEP 2000-385 - Rev 01
Status : Expired
Issue Date : 2005-02-18
Type : TSE
Substance Number : 579
Aprotinin concentrated solution
Certificate Number : R1-CEP 2000-161 - Rev 03
Status : Withdrawn by Holder
Issue Date : 2011-09-15
Type : Chemical and TSE
Substance Number : 579
Certificate Number : R0-CEP 2007-122 - Rev 00
Status : Expired
Issue Date : 2008-03-04
Type : TSE
Substance Number : 580
Bovine Aprotinin, (Catalogue Number 7107)
Certificate Number : R1-CEP 2000-208 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2006-03-07
Type : TSE
Substance Number :
Certificate Number : R1-CEP 2002-095 - Rev 06
Status : Valid
Issue Date : 2023-06-30
Type : Chemical and TSE
Substance Number : 579
Aprotinin, Concentrated solution; Freeze-dried powder
Certificate Number : R1-CEP 2000-023 - Rev 03
Status : Valid
Issue Date : 2023-06-27
Type : TSE
Substance Number : 580
Trypsin, Product numbers T5429, T7309 and T8315
Certificate Number : R1-CEP 2000-218 - Rev 03
Status : Valid
Issue Date : 2009-02-06
Type : TSE
Substance Number : 694
Trypsin, TPCK-treated, Product numbers T3053 and T3943
Certificate Number : R1-CEP 2000-214 - Rev 04
Status : Valid
Issue Date : 2009-02-06
Type : TSE
Substance Number : 694
Aprotinin, Freeze-dried powder, Bacterial Endotoxin Free
Certificate Number : R1-CEP 2002-096 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2009-07-29
Type : Chemical and TSE
Substance Number : 580
Certificate Number : R0-CEP 2000-350 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2005-03-04
Type : TSE
Substance Number : 694
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Registration Number : 228MF10181
Registrant's Address : Dornacherstrasse 112, CH-4147 Aesch, Switzerland
Initial Date of Registration : 2016-09-08
Latest Date of Registration : 2019-04-03
Aprotinin Concentrate (for manufacturing only)
Registration Number : 218MF11023
Registrant's Address : Dornacherstrasse 112, CH-4147 Aesch, Switzerland
Initial Date of Registration : 2006-12-28
Latest Date of Registration : 2017-12-25
Registration Number : 217MF10189
Registrant's Address : Osaka Prefecture, Osaka City, Nishi Ward, Awaza 1-12-18
Initial Date of Registration : 2005-06-06
Latest Date of Registration : 2016-08-19
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
NDC Package Code : 55463-0031
Start Marketing Date : 2007-02-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
About the Company : BBT Biotech GmbH is a Contract Service Organization (CSO) in the worldwide growing bio-pharmaceutical industry. We have expertise in sophisticated manufacturing systems of therapeu...
About the Company : World leading manufacturing facility in accordance with GMP standard. Over 10 years of large scale production experience provide confidence on our product stability and quality con...
About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...
About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...
About the Company : ENOMARK Group of Companies stands as a prominent Contract Manufacturer, boasting a cutting-edge manufacturing facility in Ahmadabad (Gujarat) that complies with WHO-GMP standards. ...
About the Company : Hanways Chempharm Co., Limited, the former one is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We are engaged in supplying APIs, pharmaceutical intermediate...
About the Company : Adapting quickly to the ever-evolving demands, we have emerged as one of the fastest growing organization in the pharmaceutical industry across the globe. With our headquarters loc...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
Regulatory Info : Schedule D
Registration Country : Canada
Brand Name : ARTISS
Dosage Form : SOLUTION
Dosage Strength : 3000KIU/ML
Packaging : 2ML/4ML/10ML (TOTAL VOLUME)
Approval Date :
Application Number : 2326167
Regulatory Info : Schedule D
Registration Country : Canada
Regulatory Info : Schedule D
Registration Country : Canada
Brand Name : TISSEEL
Dosage Form : SOLUTION
Dosage Strength : 3000KIU/ML
Packaging : 2ML/4ML/10ML (TOTAL VOLUME)
Approval Date :
Application Number : 2326175
Regulatory Info : Schedule D
Registration Country : Canada
Regulatory Info : Schedule D
Registration Country : Canada
Brand Name : TISSEEL
Dosage Form : KIT
Dosage Strength : 3000KIU/ML
Packaging : 2ML/4ML/10ML
Approval Date :
Application Number : 2326132
Regulatory Info : Schedule D
Registration Country : Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
